Synthesis, Computational Chemical Study, Antiproliferative Activity Screening, and Molecular Docking of Some Thiophene-Based Oxadiazole, Triazole, and Thiazolidinone Derivatives

Amna S. Elgubbi<sup>1</sup>, Eman A. E. El-Helw<sup>2,\*</sup>, Abdullah Y. A. Alzahrani<sup>3</sup>, Sayed K. Ramadan<sup>2</sup>

<sup>1</sup> Chemistry Department, Faculty of Science, Misurata University, 2478, Misurata, Libya

<sup>2</sup>Chemistry Department, Faculty of Science, Ain Shams University, Cairo, 11566, Egypt

<sup>3</sup> Chemistry Department, Faculty of Science and Arts, King Khalid University, Mohail Assir, Abha, Saudi Arabia

\**E*-mail: <u>eman.abdelrahman@sci.asu.edu.eg</u>

**Supporting information:** 

## **Figures:**



Fig. 1. Some clinical drugs bearing thiophene scaffolds as anticancer agents.



Fig. 2. Rationale and design of the chemical structures of some anticancer agents (bearing thiophene nucleus) and the target derivatives.



Compound 3



Compound 4



Compound 5



Compound 6





Compound 15





Doxorubicin

Fig. 3. Optimized structures (left), HOMO (middle), and LUMO (right) for substances 3-18 and Doxorubicin. Atom color index: Grey C, White H, Blue N, Red O, Yellow S, and Green Cl.



Fig. 4.  $IC_{50}$  values of the tested compounds against MCF7 and HCT116 cell lines.



Fig. 5. SAR of compounds 7, 8, 11a, b, 15, and 16.



\*Hydrogen bonds are illustrated as arrows; C atoms are colored gray, N blue, and O red



Fig. 6. 2D and 3D-interactions of compounds 11a, 11b, 15, and 16 with CA IX protein binding pockets.



Fig. 7. 3D diagram displays the overlay of the native co-crystallized ligand, Etoposide (in cyan), with the redocked co-crystallized ligand (in red) within the CA IX protein target.

Molecule 1			
# OOP			Water Solubility
	LIPO	Log S (ESOL) 😣	-5.18
		Solubility	2.47e-03 mg/ml ; 6.63e-06 mol/l
I	FLEX SIZE	Class 😣	Moderately soluble
0 NH		Log S (Ali) 😣	-6.04
1		Solubility	3.41e-04 mg/ml ; 9.16e-07 mol/l
The second		Class 😣	Poorly soluble
N-M	BIGATU DOLAD	Log S (SILICOS-IT) 😣	-7.27
$\geq$	HISHID POLA	Solubility	2.01e-05 mg/ml ; 5.40e-08 mol/l
	1	Class ()	Poorly soluble
2	INSOLU		Pharmacokinetics
SMILES O=C(c1cccs1)N/N	I=C/c1cn(nc1c1ccccc1)c1ccccc1	GI absorption 😣	High
Pł	sicochemical Properties	888 permeant 😣	No
Formula	C21H16N4OS	P-gp substrate 😣	No
Molecular weight	372.44 g/mol	CYP1A2 inhibitor 😣	Yes
Num. heavy atoms	27	CYP2C19 inhibitor 😣	Yes
Num. arom. heavy atoms	22	CYP2C9 inhibitor 😣	Yes
Fraction Csp3	0.00	CYP2D6 inhibitor 😣	No
Num. rotatable bonds	8	CYP3A4 inhibitor 69	Yes
Num. H-bond acceptors	3	Log K <sub>o</sub> (skin permeation) 📀	-5.39 cm/s
Num. H-bond donors	1		Druglikeness
Molar Refractivity	108.05	Lipinski 😣	Yes; 0 violation
IPSA 💔	87.92 AT	Ghose 😣	Yes
R (1.000) 0	cipoprinicity	Veber 😣	Yes
LOU Palw (ILUGP)	3.18	Egan 😣	Yes
Log P <sub>alw</sub> (XLOGP3) 😣	4.48	Muegge 😣	Yes
Log P <sub>olw</sub> (WLOGP) 😣	4.36	Bioavailability Score 😣	0.55
Log P <sub>olw</sub> (MLOGP) 🥹	3.18		Medicinal Chemistry
Log P <sub>olw</sub> (SILICOS-IT) 😣	4.67	PAINS 😣	0 alert
Consensus Log P 0	3.98	Brenk 🤨	1 alert: imine_1 🥹
- o . OW	8505.5m)	Leadlikeness 😣	No; 2 violations: MW>350, XLOGP3>3.5
		Synthetic accessibility 😣	3.18

Fig. 8. ADME prediction of compound 11a.

			Water Calub Zite
	LIPO		Vvater Solubility
		Log S (ESOL) 🥹	-4.23
		Solubility	1.96e-02 mg/ml ; 5.90e-05 mol/l
A Contraction of the second se	FLEX	Class 🥹	Moderately soluble
		Log S (Ali) 😣	-5.08
		Solubility	2.74e-03 mg/ml ; 8.24e-06 mol/l
° ×		Class 😣	Moderately soluble
H		Log S (SILICOS-IT) 😣	-6.08
	POLAT	Solubility	2.77e-04 mg/ml ; 8.34e-07 mol/l
		Class 😣	Poorly soluble
	INSOLU		Pharmacokinetics
SMILES Clc1ccc2c(c1)c(=	O)c(co2)/C=N/NC(=O)c1cccs1	GI absorption 😣	High
Pł	sicochemical Properties	BBB permeant 😣	No
Formula	C15H9CIN2O3S	P-gp substrate 😣	No
Volecular weight	332.76 g/mol	CYP1A2 inhibitor 😣	Yes
Num. heavy atoms	22	CYP2C19 inhibitor 😣	Yes
Num. arom. heavy atoms	15	CYP2C9 inhibitor 😣	Yes
Fraction Csp3	0.00	CYP2D6 inhibitor 😣	No
Num. rotatable bonds	4	CYP3A4 inhibitor 😣	No
Num. H-bond acceptors	4	Log K <sub>p</sub> (skin permeation) Θ	-5.98 cm/s
Num. H-bond donors	1		Druglikeness
Volar Retractivity	80.04	Lipinski 😣	Yes; 0 violation
IPSA 👽	SS.STA	Ghose 🛞	Yes
an P. (1.00P) 0	2.28	Veber 😣	Yes
Log Poly (ILOGP)	2.20	Egan 😣	Yes
Log P <sub>olw</sub> (XLOGP3) 🥹	3.31	Muegge 🥹	Yes
Log P <sub>olw</sub> (WLOGP) 😣	3.27	Bioavailability Score 🥹	0.55
Log P <sub>alw</sub> (MLOGP) 😣	1.61		Medicinal Chemistry
Log P <sub>olw</sub> (SILICOS-IT) 😣	4.74	PAINS 😣	0 alert
	3.04	Brenk 😣	1 alert: imine_1 😣
and a dw	New York	Leadlikeness 😣	Yes
		Synthetic accessibility 😣	3.08

Fig. 9. ADME prediction of compound 11b.

Molecule 3			
# 00@			Water Solubility
	LIPO	Log S (ESOL) 😣	-3.47
		Solubility	9.14e-02 mg/ml ; 3.37e-04 mol/l
I 1º	FLEX	Class 😣	Soluble
ST.		Log S (Ali) 😣	-4.46
HNM-N		Solubility	9.43e-03 mg/ml ; 3.48e-05 mol/l
L		Class 😣	Moderately soluble
•=		Log S (SILICOS-IT) 0	-4.71
HN	POLAN	Solubility	5.30e-03 mg/ml ; 1.95e-05 mol/l
		Class 😣	Moderately soluble
	INSOLU		Pharmacokinetics
SMILES_O=C(c1cccs1)N/N=C(1/C(=O)Nc2c1cccc2		GI absorption 😣	High
Ph	vsicochemical Properties	BBB permeant 😣	No
ormula	C13H9N3O2S	P-gp substrate 🔞	No
Nolecular weight	271.29 g/mol	CYP1A2 inhibitor 😣	Yes
Num. heavy atoms	19	CYP2C19 inhibitor 😣	Yes
Num. arom. heavy atoms	11	CYP2C9 inhibitor 😣	No
Fraction Csp3	0.00	CYP2D6 inhibitor 😣	No
Num. rotatable bonds	3	CYP3A4 inhibitor 😣	No
Num. H-bond acceptors	3	Log K., (skin permeation) 😣	-6.02 cm/s
Num. H-bond donors	2	o pro 1	Druglikeness
Iolar Refractivity	75.81	Lininski	Yes: 0 violation
IPSA 🥹	98.80 A=	Ghose 0	Yes
	Lipophilicity	Veher (9	Yes
.og P <sub>alw</sub> (iLOGP) 🥹	1.71	Foan 😡	Vec
.og P <sub>alw</sub> (XLOGP3) 😣	2.73	Muenne 0	Yes
.og P <sub>olw</sub> (WLOGP) 🥹	1.26	Ricavailability Score 6	0.55
og Poly (MLOGP) (	1.18	side randomity ocore of	Medicinal Chemistry
	3.00	PAINS 0	1 alert: imine one isatin 😣
		Brenk 😣	1 alert: imine 1 0
Consensus Log P <sub>olw</sub> 🤫	1.97	Leadlikeness 😣	Yes
		Synthetic accessibility	2.67

Fig. 10. ADME prediction of compound 15.

Molecule 4			
# 0 O P			Water Solubility
	LIPO	Log S (ESOL) Θ	-3.24
	=0	Solubility	1.82e-01 mg/ml ; 5.80e-04 mol/l
HN	FLEX SIZE	Class 😣	Soluble
T N		Log S (Ali) 😣	-3.64
« T 1	N	Solubility	7.21e-02 mg/ml ; 2.30e-04 mol/l
E Y		Class 😣	Soluble
)	POLA	R Log S (SILICOS-IT) 😣	-4.37
S		Solubility	1.35e-02 mg/ml ; 4.32e-05 mol/l
		Class 😣	Moderately soluble
	INSOLU		Pharmacokinetics
SMILES CC(=O)N1N=C(C	DC21C(=O)Nc1c2cccc1)c1cccs1	GI absorption 😣	High
PI	hysicochemical Properties	888 permeant 😣	No
Formula	C15H11N3O3S	P-gp substrate 😣	No
Molecular weight	313.33 g/mol	CYP1A2 inhibitor 😣	No
Num. heavy atoms	22	CYP2C19 inhibitor 😣	No
Num. arom. heavy atoms	11	CYP2C9 inhibitor 😣	No
Fraction Csp3	0.13	CYP2D6 inhibitor 😣	No
Num. rotatable bonds	2	CYP3A4 inhibitor 😣	No
Num. H-bond acceptors	4	Log K., (skin permeation) 😣	-6.84 cm/s
Num. H-bond donors	1	o pr	Druplikeness
Molar Refractivity	91.40	Lipinski 🕖	Yes: 0 violation
TPSA 🥹	99.24 A⁼	Ghose ()	Yes
	Lipophilicity	Veber 😣	Yes
Log P <sub>olw</sub> (iLOGP) 😣	2.57	Egan 😣	Yes
Log P <sub>alw</sub> (XLOGP3) 🥹	1.93	Muegge 😣	Yes
Log P <sub>alw</sub> (WLOGP) 😣	0.65	Bioavailability Score 😣	0.55
Log P <sub>olw</sub> (MLOGP) 😣	2.35		Medicinal Chemistry
Log Poly (SILICOS-IT) 😣	2.91	PAINS 😣	0 alert
	2.08	Brenk Θ	0 alert
Conservation 20/8 - 0/W	2.00	Leadlikeness 😣	Yes
		Synthetic accessibility 😣	4.18

Fig. 11. ADME prediction of compound 16.

Spectral Data:





114\*























































